Yang Lichun, Wang Bochu, Qiao Weili, Liu Peng
College of Bioengineering, Chongqing University, Chongqing 400030, PR China.
Med Hypotheses. 2009 Sep;73(3):334-5. doi: 10.1016/j.mehy.2009.04.002. Epub 2009 May 6.
The effects of conventional systemic chemotherapy are very modest, while the side-effects are very severe. Thus, intratumoral chemotherapy emerges as a new adjuvant treatment modality due to its several potential advantages. However, most researchers currently select only single cytotoxic drug as model drug at present studies, while ignore the combination administration. So, we hypothesize whether we can integrate the advantages of combination chemotherapy and intratumoral chemotherapy to achieve good antitumour effectiveness and minimal systemic side-effects and resistance. We propose that several drugs based on the cancer cell cycle are reserved in the microsphere-gel. Firstly, cell cycle specific agents (CCSA) are encapsulated into microspheres, then cell cycle non-specific agents and CCSA-loaded microspheres are dispersed into pre-gel solution. Eventually the goal of sequential, intermittent and combination chemotherapy is achieved. Therefore, the hypothesis has the potential application to treat cancer owing to its advantages of targeting effect, high efficiency, low side-effects and resistance, convenience.
传统全身化疗效果甚微,而副作用却极为严重。因此,瘤内化疗因其诸多潜在优势成为一种新的辅助治疗方式。然而,目前大多数研究人员在当前研究中仅选择单一细胞毒性药物作为模型药物,却忽略了联合给药。所以,我们推测是否可以整合联合化疗和瘤内化疗的优势,以实现良好的抗肿瘤效果、最小的全身副作用和耐药性。我们建议将几种基于癌细胞周期的药物保留在微球凝胶中。首先,将细胞周期特异性药物(CCSA)封装入微球,然后将细胞周期非特异性药物和负载CCSA的微球分散到预凝胶溶液中。最终实现序贯、间歇和联合化疗的目标。因此,该假说因其具有靶向效应、高效、低副作用和耐药性、方便等优势,具有治疗癌症的潜在应用价值。